window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 16, 2025

  • News
  • About Us
Contact Us

MHRA

  • Central Nervous System,Clinical Development,Market Access & Commercialization,Patient Centricity,Pharmaceuticals and therapeutics

    Bristol Myers Squibb to launch Cobenfy in the UK at US list price for adults with schizophrenia

    Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium [...]

    September 23, 2025
  • Clinical Trials,Drug approval,Oncology,Pharmaceuticals and therapeutics

    Servier receives UK marketing authorisation for vorasidenib for low grade glioma

    Servier has received marketing authorisation from the Medicines and Healthcare [...]

    September 22, 2025
  • Medical devices

    Morphic Medical appoints Jane Wright as chief financial officer during European rollout of Reset

    Appointment strengthens leadership team as company expands access to its [...]

    September 15, 2025
  • CDMOs & Manufacturing,Pharmaceuticals and therapeutics,Regulatory Affairs

    Symbiosis expands quality leadership with new qualified person appointment

    Symbiosis Pharmaceutical Services has appointed Wendy Cook as a qualified [...]

    September 14, 2025
  • Clinical Development,Pharmaceuticals and therapeutics,Regulatory Affairs

    MHRA grants Promising Innovative Medicine designation to TransCon CNP for achondroplasia

    Ascendis Pharma UK Limited announced that TransCon CNP (navepegritide) has [...]

    September 9, 2025
  • Artificial Intelligence,Digital Health,Medical devices,Movers & Shakers,Patient Centricity,Regulatory Affairs

    AI tool could spot hospital infections up to 72 hours early

    Sanome’s MEMORI becomes the first UK-developed AI medical device to [...]

    August 20, 2025
  • Biologics & Biosimilars,CDMOs & Manufacturing,Drug Development,Regulatory Affairs,Supply Chain & Logistics

    Symbiosis completes 1,000th batch of sterile injectable drug product

    Contract manufacturer Symbiosis Pharmaceutical Services has announced the completion of [...]

    July 31, 2025
  • Drug Development,Patient Centricity,Rare Diseases,Regulatory Affairs

    MHRA approves Biogen’s tofersen for ultra-rare genetic form of motor neurone disease

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has [...]

    July 28, 2025
  • Clinical Development,Drug Delivery & Formulation,Drug Development,Medical devices,Regulatory Affairs

    MHRA approval expected soon for non-surgical weight loss device RESET

    Morphic Medical’s non-invasive weight loss device RESET is expected to [...]

    July 18, 2025
  • Biologics & Biosimilars,Clinical Development,Patient Centricity,Regulatory Affairs

    NICE recommends Mirikizumab for moderately to severely active Crohn’s Disease after biologic failure

    Mirikizumab is now recommended by NICE for routine NHS use [...]

    July 14, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top